How's biotech doing in China?

How should you talk to friends about rejection? And can Facebook actually improve the lives of children?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we talk about the FDA's surprise decision to reject a drug from Sarepta Therapeutics — and the company's curious way of explaining it. Then, STAT's Shraddha Chakradhar joins us to talk about the growing online community devoted to helping toddlers get access to Zolgensma, Novartis's $2.1 million rare disease treatment. Finally, biotech investor Brad Loncar dials in to explain how the Chinese biotech sector has evolved and where it's headed.

You can listen to the episode here. To listen to future episodes, be sure to sign up on iTunes, Stitcher, Spotify, or wherever you get your podcasts.